EP0252974A1 - Enhancement of enzymatic activity in cleaning contact lenses by the use of hypotonic solutions. - Google Patents

Enhancement of enzymatic activity in cleaning contact lenses by the use of hypotonic solutions.

Info

Publication number
EP0252974A1
EP0252974A1 EP87900942A EP87900942A EP0252974A1 EP 0252974 A1 EP0252974 A1 EP 0252974A1 EP 87900942 A EP87900942 A EP 87900942A EP 87900942 A EP87900942 A EP 87900942A EP 0252974 A1 EP0252974 A1 EP 0252974A1
Authority
EP
European Patent Office
Prior art keywords
enzyme
solution
lenses
contact lenses
cleaning
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP87900942A
Other languages
German (de)
French (fr)
Other versions
EP0252974B1 (en
EP0252974A4 (en
Inventor
Stanley W Huth
Sam W Lam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Surgical Vision Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to AT87900942T priority Critical patent/ATE83179T1/en
Publication of EP0252974A1 publication Critical patent/EP0252974A1/en
Publication of EP0252974A4 publication Critical patent/EP0252974A4/en
Application granted granted Critical
Publication of EP0252974B1 publication Critical patent/EP0252974B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/0005Other compounding ingredients characterised by their effect
    • C11D3/0078Compositions for cleaning contact lenses, spectacles or lenses
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/38Products with no well-defined composition, e.g. natural products
    • C11D3/386Preparations containing enzymes, e.g. protease or amylase
    • C11D3/38618Protease or amylase in liquid compositions only

Abstract

Hypotonic solutions enhance enzymatic activity in proteolytic cleaning of contact lenses. The hypotonic solution may have an osmolality value ranging between 0 and 275 mOsm/kg, but preferably will be between 100 and 200 mOsm/kg.

Description

ENHANCEMENT OF ENZYMATIC ACTIVITY IN CLEANING CONTACT LENSES BY THE USE OF HYPOTONIC SOLUTIONS
Background This invention relates to the potentiation of the enzymatic activity in cleaning contact lenses. More specifically, this invention is a method for potentiating the proteolytic activity of proteases in the cleaning of contact lenses by carrying out the cleaning in a hypotonic solution.
Related Art
Contact lenses, particularly those with a hydrophilic surface such as the hydrogel lenses and the hard, gas permeable lenses with a treated surface, encounter protein accretions during normal wear. It is beneficial, if not often times necessary, to remove these accretions in order to maintain visual acuity, prevent eye irritation and to prevent the development of giant papillary conjunctivitis.
The use of proteolytic enzymes has been developed to remove such deposits. See. for example. U.S. Patent 3,910,296. and 4,285,738. The '296 disclosure makes no comment on the effect of tonicity value on enzyme activity. The '738 patent discloses in the specification and stipulates in the claim, that the solution must be hypertonic. Hypertonic is not specifically defined, but the urea concentration is specified as being between 5% through saturation (weight/volume). The normal tonicity value is that of a physiological solution as illustrated by the 0.9% by weight/volume concentration of aqueous saline.
It has now been found that where the enzymatic solution is made hypotonic, removal of adhered protein by the enzyme is substantially enhanced throughout the effective pH range of the enzyme. Studies were carried out with several enzymes, papain. subtilisin. pancreatin. each of which clearly demonstrated a substantial increase in activity when the solution was made hypotonic,
Summary of the Invention This invention covers a method for enhancing the activity of an enzyme used in the cleaning of contact lenses, which method comprises carrying out the cleaning regime in a solution having an osmolality value up to about 275 milliosmoles/kilogram.
Specific Embodiments
The use of a hypotonic solution to enhance enzyme activity for cleaning contact lenses is applicable to any proteolytic enzyme which may be used to remove protein from contact lenses.
Tonicity values may range from 0 up to about 275 mOsm/kg. The enzyme itself will be active at tonicity values close to 0. but as a practical matter it is difficult to prepare such solutions because of the solutes normally present in diluents, including purified water. Tests have been carried out where the osmolality was as low as 6 mOsm/kg. A more preferred lower limit is about 50 mOsm/kg. which number allows for the addition of small amounts of salts, stabilizers, enzyme co-factors or other excipients which may be useful and beneficial to solution stability, enzyme activity or the like.
On the upper side. 275 milliosmoles is approximately the top end of the range so far as enjoying substantially enhanced proteolytic activity is concerned. More preferably, the upper limit will be between 175 and 200 mOsm/kg.
The adjustment of tonicity value can be made with any number of excipients and constituents well known in the art. If an enzyme co-factor is critical or essential to the cleaning process, obviously its presence must be given primary consideration in adding materials to the formulation. Salts of any sort including salts which are necessary co-factors for enzymatic activity such as calcium should be accounted for in formulating these hypotonic solutions. The hypotonic value is determined, that is measured, after addition of the enzyme.
In the following examples, the ability of a given solution and enzyme to remove protein from a contact lens was determined by essentially the same procedure each time. Generically. the procedure was to take a contact lens and coat it with heat denatured lysozyme by placing the lens in a phosphate buffered saline solution to which was then added sufficient lysozyme to make a 0.1% solution by weight. The lysozyme was from egg white. These solutions were then heated for 30 minutes at about 95 C. The lenses were removed, cooled and rinsed with distilled water and viewed to determine what type of lysozyme accretion was on the lens at time zero.
Protein deposit classification (typing): as a means for quantifying the proteolytic activity of enzymes in removing absorbed protein from the lenses, a system was developed whereby the protein on the lenses was visually quantified before and after enzyme treatment.
After a lens had been heated for 30 minutes in the lysozyme solution, the lens was wetted with distilled water, rubbed between the thumb and finger, then grasped by the edge with plastic tweezers and rinsed with distilled water again. The convex side of the lens was viewed under a microscope at 100X magnif ication. A film or deposit detected under these conditions was classified according to the percentage of the lens surface covered by the deposit. The protein removal efficacy of an enzyme solution is expressed in terms of the percentage of the lens surface which has been cleaned. This number is derived by subtracting the percentage of the lens surface covered by the protein deposit from 100%.
Example 1
Effect of Osmolality Twenty-four Hydrocurve® II hydrogel lenses (Barnes-Hind. Inc. Sunnyvale. California) were coated with lysozyme using the standard procedure. Each was viewed after treatment and determined to have at least 98% of its surface covered by a protein film. In most cases. 100% of the lens surface was covered by a protein film. A subtilisin enzyme containing solution was prepared as follows: cysteine hydrochloride monohydrate (1.001g), sodium borate dihydrate (1.911 g), sodium carbonate anhydrous (3.106g), polyethylene glycol 3350 (0.403g). tartaric acid (2.002g). S. carlsberg (0.041g). obtained from Novo Industries of Denmark, was dissolved in 300 ml of purified water, the pH adjusted to 8.4 with sodium hydroxide or hydrochloric acid, and then water added in a quantity sufficient to make 1000 ml. Three 200 ml portions were removed and the osmolality adjusted with sodium chloride and the pH with NaOH or HCl as needed to obtain the figures given in table I. Three lenses were soaked in each of the solutions for 3 hours at room temperature, then a determination of percentage residual protein deposit and cleaned lens surface made as per the standard procedure described above. TABLE I - Effect of Osmolality Average % Lens Surface Cleaned pH
9 98.3±2 .9 23.3±5.8 11.7±5.8
8.5 100 11.7±2.9 13.3±2.9
7.8 90±17 3.3±2.9
150 326 420 Osmolality (mOsm/kg)
Table I shows that greater cleaning was observed at 150 mOsm/kg than at either 326 or 420 mOsm/kg.
Example 2 Effect of pH vs. Osmolality
Hydrogel-type lenses (Hydrocurve II®. 55% water, sold by Barnes-Hind. Inc.) were treated with heat-denatured lysozyme as described above.
A subtilisin-A-containing solution was prepared (0.04 mg/ml of water without excipients. activity: 0.0012 Au/ml) in such a manner as to have pH values between approximately 5.0 and 10.0. The osmolality value was then adjusted to 6. 133 and 264 mOsm/kg with NaCl for each of these solutions, each of the tonicity values being tested at pH 9.0. Lenses were then soaked in these solutions (five in each) for 2 hours at room temperature, rinsed, and analyzed for percentage residual protein deposit as described above. Results are given in Table II.
Table II - Effect of pH vs. Osmolality
% Lens Surface Cleaned pH
10.0 93.0±4.5
9.0 69.0±8.2 34.0±5.5 18.0±2.7 8.0 62.0±4.5
7.0 58.0±4.5
6.0 23.8±4.8*
5.0 11.0±2.2
6 133 264
Osmolality (mOsm/kg)
* only four lenses.
It can be seen from the data presented in Table II that both solution pH and osmolality are important parameters asserting the cleaning efficacy of an enzyme solution. Since subtilisin-A is an alkaline protease, having its greatest activity between pH 8 and 10, the greatest cleaning efficacy is observed in this pH range also.
Example 3 Lenses with lysozyme protein deposits covering at least 98% of the lens surface were cut in half, one half being soaked in one enzyme solution and the other in another enzyme solution in the first comparison (pancreatin data); whole lenses were used in the other studies. The enzyme solutions were comprised of enzyme and excipients as indicated in Table III. Lenses were bufilcon-A sold by Barnes-Hind, Inc. under the name Hydrocurve II®. Results from each of the several formulations are listed in the following table. The abbreviation DI is used for deionized water. Table I I I
Effect of Varying Osaolality on Enzyme Cleaning Efficacy
OsmolSoak Average
Enzyme Used Diluent pH ality Time % Cleaning
Pancreatin1 DI water 8.58 175 4 hrs 32.0±25.4 Pancreatin saline2 7.97 382 4 hrs 1.3±2.3
Subtilisin carlsberg DI water 8.43 157 3 hrs 98.3±2.9 0.04 mq/ml3 water & 8.43 335 3 hrs 25.6±13.9 NaCl
Subtilisin carlsberg DI water 8.86 124 1 hr 79.6+11.3
0.04mg/ml4 saline 8.21 418 2 hrs 16.4+.4.6
1. Alcon Optizyme" tablet.
2. Normal saline.
3. Same formulation excipients as in Example 1, Table I.
4. A subtilisin enzyme tablet was dissolved in either 10ml of DI water or saline. Each enzyme tablet contained: 30mg N-acetylcysteine, 34mg sodiua carbonate, 7mg tartaric acid, 4mg polyethylene glycol 3350, 4mg subtillsin-A (subtilisin carlsberg from NOVO Industries of Denmark), and 50mg of lactose.
5. Allergan Hydrocare" Preserved Saline.
It can be seen from the data presented in Table III that for both pancreatin and Subtilisin carlsberg. the solutions with the lowest tonicity produced the highest cleaning efficacy. Example 4
The effect of osmolality values on cleaning efficacy was investigated with papain enzyme. Solutions of lmg/ml papain, lmg/ml L-cysteine and 0.8mg/ml EDTA at 95mOsm/kg, 193mOsm/kg and 291mOsm/kg were tested (pH 8.4).
Hydrocurve II lenses (55% H2O) from Barnes-Hind were coated with denatured lysozyme as described in Example 1. Three lenses were soaked in the 95mOsm/kg solution and four lenses in each of the other two solutions. Soaking time was 3.5 hours. Total percent surface cleaned was determined as per Example 1. the results are given in Table IV.
Table IV
%Surface
Lens Cleaned Mean + S.D. Exp. Conditions
A1 100 78±38 lmg/ml papain, lmg/ml
A2 35 L-cysteine .8mg/ml EDTA
A3 100 pHf=8.4 osmolality=95mOsm/1kg
B1 60 48±28 Same as above except
B2 30 osmolality = 193mOsm/1kg
B3 80
B4 20
C1 30 21±12 Same as above except
C2 20 osmolality = 291mOsm/1kg
C3 5
C4 30
It can be seen from the data presented in Table IV that cleaning efficacy increases with lower solution tonicity for papain-containing solutions.

Claims

WHAT IS CLAIMED I S :
1. A method for enhancing the activity of an enzyme used in the cleaning of contact lenses, which method comprises carrying out the cleaning regimen in a solution having an osmolality value up to 275 mOsm/kg.
2. The method of claim l wherein the osmolality is between 100 and 200 mOsm/kg.
EP87900942A 1986-01-06 1987-01-05 Enhancement of enzymatic activity in cleaning contact lenses by the use of hypotonic solutions Expired - Lifetime EP0252974B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT87900942T ATE83179T1 (en) 1986-01-06 1987-01-05 INCREASING ENZYMATIC ACTIVITY IN CLEANING CONTACT LENSES BY USING HYPOTONIC SOLUTIONS.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81651886A 1986-01-06 1986-01-06
US816518 1986-01-06

Publications (3)

Publication Number Publication Date
EP0252974A1 true EP0252974A1 (en) 1988-01-20
EP0252974A4 EP0252974A4 (en) 1988-05-03
EP0252974B1 EP0252974B1 (en) 1992-12-09

Family

ID=25220860

Family Applications (1)

Application Number Title Priority Date Filing Date
EP87900942A Expired - Lifetime EP0252974B1 (en) 1986-01-06 1987-01-05 Enhancement of enzymatic activity in cleaning contact lenses by the use of hypotonic solutions

Country Status (6)

Country Link
EP (1) EP0252974B1 (en)
AT (1) ATE83179T1 (en)
AU (1) AU6898887A (en)
DE (1) DE3782981T2 (en)
HK (1) HK113995A (en)
WO (1) WO1987004091A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5630884A (en) * 1993-06-17 1997-05-20 Allergan Methods for contact lens cleaning
US5783532A (en) * 1993-06-17 1998-07-21 Allergan Enzyme compositions and methods for contact lens cleaning

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037647A (en) * 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
CA2009118C (en) * 1989-02-21 1996-02-27 Mary F. Mowrey-Mckee Method and composition for cleaning and disinfecting contact lenses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2088581A (en) * 1980-10-02 1982-06-09 Smith & Nephew Associated Cie Papain and lactose containing tablet for cleaning contact lenses
GB2117534A (en) * 1982-03-31 1983-10-12 Smith & Nephew Ass Papain containing tablet for cleaning contact lenses
EP0219220A1 (en) * 1985-09-09 1987-04-22 Allergan, Inc Method and composition for the simultaneous cleaning and disinfecting of contact lenses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3240709A (en) * 1962-05-16 1966-03-15 Burton Parsons Chemicals Inc Method of cleansing contact lenses
US3910296A (en) * 1973-04-20 1975-10-07 Allergan Pharma Method of removing proteinaceous deposits from contact lenses
US4048122A (en) * 1976-01-23 1977-09-13 Barnes-Hind Pharmaceuticals, Inc. Cleaning agents for contact lenses
JPS54140553A (en) * 1978-04-24 1979-10-31 Senju Pharma Co Contact lens washing liquid
US4263054A (en) * 1979-02-23 1981-04-21 George D. Weaver Contact lens cleaning and rinsing method
US4521254A (en) * 1981-02-09 1985-06-04 Anderson Ronald L Cleaning contact lenses with solution of bromelain and carboxypeptidase
US4626292A (en) * 1982-06-01 1986-12-02 Sherman Laboratories, Inc. Soft contact lens wetting and preservation method
US4613380A (en) * 1985-04-01 1986-09-23 Dow Corning Corporation Method for removing lipid deposits from contact lenses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2088581A (en) * 1980-10-02 1982-06-09 Smith & Nephew Associated Cie Papain and lactose containing tablet for cleaning contact lenses
GB2117534A (en) * 1982-03-31 1983-10-12 Smith & Nephew Ass Papain containing tablet for cleaning contact lenses
EP0219220A1 (en) * 1985-09-09 1987-04-22 Allergan, Inc Method and composition for the simultaneous cleaning and disinfecting of contact lenses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO8704091A1 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5630884A (en) * 1993-06-17 1997-05-20 Allergan Methods for contact lens cleaning
US5783532A (en) * 1993-06-17 1998-07-21 Allergan Enzyme compositions and methods for contact lens cleaning
US6165954A (en) * 1993-06-17 2000-12-26 Allergan, Inc. Enzyme compositions and methods for contact lens cleaning

Also Published As

Publication number Publication date
EP0252974B1 (en) 1992-12-09
WO1987004091A1 (en) 1987-07-16
AU6898887A (en) 1987-07-28
DE3782981D1 (en) 1993-01-21
EP0252974A4 (en) 1988-05-03
DE3782981T2 (en) 1993-04-08
HK113995A (en) 1995-07-21
ATE83179T1 (en) 1992-12-15

Similar Documents

Publication Publication Date Title
EP0772669B1 (en) Saline solution for treating contact lenses
US20050282715A1 (en) Use of multifunctional surface active agents to clean contact lenses
US4521254A (en) Cleaning contact lenses with solution of bromelain and carboxypeptidase
JPH07168145A (en) Cleaning and disinfecting agent for contact lens
WO1994006479A1 (en) Non-oxidative method and composition for simultaneously cleaning and disinfecting contact lenses
JP2002504399A (en) Treatment of contact lenses using aqueous solutions containing alkali carbonates
KR100253435B1 (en) Stable liquid enzyme compositions and methods of use in contact lens cleaning and disinfecting systems
EP0257821A1 (en) Contact lens cleaning solution
US6136850A (en) Methods and compositions for inhibiting deposit formation on contact lenses
EP0666899B1 (en) Cleaning and disinfecting contact lenses
EP0252974B1 (en) Enhancement of enzymatic activity in cleaning contact lenses by the use of hypotonic solutions
US4921630A (en) Contact lens cleaning compositions containing an enzyme and a carboxy vinyl polymer
AU677093B2 (en) Method of stabilizing preparations for contact lenses
EP1458420A2 (en) Composition for treating contact lenses
CA1265079A (en) Enhancement of enzymatic activity in cleaning contact lenses by use of hypotonic solutions
JP2005513112A (en) Composition for treating contact lenses in the eye
US6214596B1 (en) Liquid enzyme compositions and methods of use in contact lens cleaning and disinfecting systems
JPH09263795A (en) Cleaning solution for contact lens and method for cleaning contact lens therewith
US5209783A (en) Method for simultaneously cleaning, decolorizing and thermally disinfecting contact lenses
WO1985003247A1 (en) Method for cleaning contact lenses
JP3552838B2 (en) Contact lens solution and cleaning and disinfecting method using the same
JP3112783B2 (en) How to wash, store and sterilize contact lenses
JP2003121805A (en) Method for cleaning and disinfecting contact lens
JP3983906B2 (en) Enzyme-containing contact lens solution
JPH04296714A (en) Method for simultaneously performing cleaning, discoloring, heating and disinfection for contact lens

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19871026

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19880503

17Q First examination report despatched

Effective date: 19890420

ITTA It: last paid annual fee
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 83179

Country of ref document: AT

Date of ref document: 19921215

Kind code of ref document: T

ET Fr: translation filed
REF Corresponds to:

Ref document number: 3782981

Country of ref document: DE

Date of ref document: 19930121

ITF It: translation for a ep patent filed

Owner name: BARZANO' E ZANARDO MILANO S.P.A.

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
EPTA Lu: last paid annual fee
EAL Se: european patent in force in sweden

Ref document number: 87900942.1

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19971222

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19980108

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19980109

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19980115

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990105

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990105

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990131

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990131

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990131

BERE Be: lapsed

Owner name: ALLERGAN INC.

Effective date: 19990131

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20030131

Year of fee payment: 17

NLS Nl: assignments of ep-patents

Owner name: ADVANCED MEDICAL OPTICS, INC.

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040803

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20041216

Year of fee payment: 19

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20041229

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20050117

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20050120

Year of fee payment: 19

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060105

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060106

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060131

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20060131

Year of fee payment: 20

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060801

EUG Se: european patent has lapsed
GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20060105

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20060801

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20060929